These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
107 related items for PubMed ID: 2318945
1. Blindness impairs plasma growth hormone response to L-dopa but not to arginine. Bellastella A, Parlato F, Sinisi AA. J Clin Endocrinol Metab; 1990 Apr; 70(4):856-8. PubMed ID: 2318945 [Abstract] [Full Text] [Related]
2. In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose. Maccario M, Procopio M, Grottoli S, Oleandri SE, Razzore P, Camanni F, Ghigo E. J Clin Endocrinol Metab; 1995 Dec; 80(12):3774-8. PubMed ID: 8530634 [Abstract] [Full Text] [Related]
3. Growth hormone (GH) responses to arginine and L-dopa alone and after GHRH pretreatment. Page MD, Dieguez C, Valcavi R, Edwards C, Hall R, Scanlon MF. Clin Endocrinol (Oxf); 1988 May; 28(5):551-8. PubMed ID: 3145820 [Abstract] [Full Text] [Related]
5. L-Dopa stimulated growth hormone release in the blind. Bellastella A, Colucci CF, D'Alessandro B, Lo Cicero M. J Clin Endocrinol Metab; 1977 Jan; 44(1):194-5. PubMed ID: 833257 [Abstract] [Full Text] [Related]
6. The inhibitory effects of growth hormone-releasing hormone (GHRH)-antagonist on GHRH, L-dopa, and clonidine-induced GH secretion in normal subjects. Hanew K, Tanaka A, Utsumi A, Sugawara A, Abe K. J Clin Endocrinol Metab; 1996 May; 81(5):1952-5. PubMed ID: 8626863 [Abstract] [Full Text] [Related]
7. [Effect of oral administration of L-dopa on the plasma levels of growth hormone-releasing hormone (GHRH) in normal subjects and patients with various endocrine and metabolic diseases]. Mitsuhashi S, Yamasaki R, Miyazaki S, Saito H, Saito S. Nihon Naibunpi Gakkai Zasshi; 1987 Aug 20; 63(8):934-46. PubMed ID: 3123283 [Abstract] [Full Text] [Related]
8. Insulin-induced hypoglycemia, L-dopa and arginine stimulate GH secretion through different mechanisms in man. Masuda A, Shibasaki T, Hotta M, Yamauchi N, Ling N, Demura H, Shizume K. Regul Pept; 1990 Oct 29; 31(1):53-64. PubMed ID: 2270318 [Abstract] [Full Text] [Related]
9. Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy. Giustina A, Bossoni S, Bodini C, Girelli A, Balestrieri GP, Pizzocolo G, Wehrenberg WB. J Clin Endocrinol Metab; 1992 Jun 29; 74(6):1301-5. PubMed ID: 1592874 [Abstract] [Full Text] [Related]
10. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome. Procopio M, Invitti C, Maccario M, Grottoli S, Cavagnini F, Camanni F, Ghigo E. Int J Obes Relat Metab Disord; 1995 Feb 29; 19(2):108-12. PubMed ID: 7735336 [Abstract] [Full Text] [Related]
11. Discordance between growth hormone (GH) responses after GH-releasing hormone and insulin hypoglycemia in myotonic dystrophy. Okimura Y, Chihara K, Kita T, Kashio Y, Sato M, Kitajima N, Abe H, Takahashi K, Fujita T. J Clin Endocrinol Metab; 1988 Nov 29; 67(5):1074-9. PubMed ID: 3141449 [Abstract] [Full Text] [Related]
12. Immunoreactive growth hormone-releasing hormone (IR-GHRH) in the feto-placental circulation and differential effects of L-dopa, L-arginine and somatostatin-14 on the plasma levels of IR-GHRH in normal adults. Saito H, Hosoi E, Yamasaki R, Kameyama K, Irahara M, Ohno Y, Saito S. Horm Metab Res; 1997 Apr 29; 29(4):184-9. PubMed ID: 9178029 [Abstract] [Full Text] [Related]
13. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine. Valcavi R, Valente F, Dieguez C, Zini M, Procopio M, Portioli I, Ghigo E. J Clin Endocrinol Metab; 1993 Sep 29; 77(3):616-20. PubMed ID: 8103770 [Abstract] [Full Text] [Related]
14. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man. Ghigo E, Goffi S, Nicolosi M, Arvat E, Valente F, Mazza E, Ghigo MC, Camanni F. J Clin Endocrinol Metab; 1990 Dec 29; 71(6):1481-5. PubMed ID: 2229304 [Abstract] [Full Text] [Related]
15. Preservation of dopaminergic and alpha-adrenergic function in children with growth hormone neurosecretory dysfunction. Bercu BB, Root AW, Shulman DI. J Clin Endocrinol Metab; 1986 Oct 29; 63(4):968-73. PubMed ID: 3018032 [Abstract] [Full Text] [Related]
16. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects. Cordido F, Dieguez C, Casanueva FF. J Clin Endocrinol Metab; 1990 May 29; 70(5):1361-70. PubMed ID: 2159483 [Abstract] [Full Text] [Related]
17. Pyridostigmine potentiates L-dopa- but not arginine- and galanin-induced growth hormone secretion in children. Ghigo E, Bellone J, Imperiale E, Arvat E, Mazza E, Valetto MR, Boffano GM, Cappa M, Loche S, De Sanctis C. Neuroendocrinology; 1990 Jul 29; 52(1):42-5. PubMed ID: 1697660 [Abstract] [Full Text] [Related]
18. Variable plasma growth hormone (GH)-releasing hormone and GH responses to clonidine, L-dopa, and insulin in normal men. Tapanainen P, Knip M, Lautala P, Leppäluoto J. J Clin Endocrinol Metab; 1988 Oct 29; 67(4):845-9. PubMed ID: 3138280 [Abstract] [Full Text] [Related]
19. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects. Arvat E, Gianotti L, Grottoli S, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E. J Clin Endocrinol Metab; 1994 Nov 29; 79(5):1440-3. PubMed ID: 7962341 [Abstract] [Full Text] [Related]
20. The role of endogenous GHRH in arginine-, insulin-, clonidine- and l-dopa-induced GH release in normal subjects. Hanew K, Utsumi A. Eur J Endocrinol; 2002 Feb 29; 146(2):197-202. PubMed ID: 11834428 [Abstract] [Full Text] [Related] Page: [Next] [New Search]